Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News

Pharma News

Breakthrough Therapy Designation Market Worth $144.6 Billion By 2025

Breakthrough Therapy Designation Market Worth $144.6 Billion By 2025

The global breakthrough therapy designation market is anticipated to reach USD 144.

Teva warns on 2018 profit, may face migraine drug delays

Teva warns on 2018 profit, may face migraine drug delays

TEL AVIV (Reuters) - Teva Pharmaceutical Industries on Thursday said its 2018 results would be weaker than expected and that it might encounter delays for an important new migraine drug, pushi...

$Verastem Seeks Approval of Duvelisib for Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma$

Verastem Seeks Approval of Duvelisib for Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma

Verastem is seeking approval of duvelisib to treat refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the U.

U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.

Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

CAMBRIDGE, Mass.

Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

CAMBRIDGE, MA, USA I February 7, 2018 I Sage Therapeutics (NASDAQ.

Just two drugmakers left bidding for Sanofi's European generics business

Just two drugmakers left bidding for Sanofi's European generics business

It has emerged that the number of industry players in the running to buy Sanofi’s (Euronext.

Array of excitement at combo’s comparison with Roche drug

Array of excitement at combo’s comparison with Roche drug

USA-based Array BioPharma (Nasdaq.

Boston’s Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

Boston’s Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

While Boston-based Intarcia Therapeutics grapples with addressing concerns raised by the U.

Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer

Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to findings from the phas...

Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)

460 461 462 463464465 466 467 468